Pompe disease is a metabolic inherited myopathy due to acid maltase (1,4-glucosidase) defi ciency with glycogen storage.
biopsy was recommended. The muscle biopsy showed changes compatible with glycogen metabolic myopathy.
In 2012, during the course of the disease, respiratory failure due to respiratory muscle weakness set in. The patient underwent pulmonary function testing and the pneumologist recommended BIPAP noninvasive ventilation, 8 hours daily during sleep.
In February 2013, the DNA PCR detected two heterozygous mutations in the GAA gene, the fi rst was located in intron 1 and the second in exon 15, and the likely diagnosis was adult-onset Pompe disease.
Since May 2013, the patient has started replacement therapy with recombinant acid α-glucosidase injected intravenously every 2 weeks with respiratory and fatigability improvement, and non-progressive motor weakness.
